N4 Pharma is a pre-clinical stage specialist pharmaceutical company developing Nuvec®, a unique novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Established in 2014 and floated on the AIM stock market in May 2017.
Nuvec® is currently in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems.
Learn more
Watch our new video animation below to see Nuvec® in action:
Latest news and updates
Poster presentation: Enhancing adenovirus gene transfer using novel nanoparticles complexes
Our research partners at Brunel University London found that adenovirus (Av) – an effective gene delivery vehicle for vaccinations – complexed with Nuvec®, can significantly improve adenovirus transduction. In the study, researchers investigated the [...]
Acquisition of Nanogenics Ltd
N4 Pharma is pleased to announce the acquisition of a controlling interest, through a subscription for new ordinary shares, in Nanogenics Limited, a company with a complementary lipid and peptide-based delivery system called LipTide®, which it [...]
News: N4 Pharma to support with the development of a new nanoparticle delivery system
The University of Queensland has announced that Professor Chengzhong Yu, Senior Group Leader, Australian Institute for Bioengineering and Nanotechnology (AIBN) has been awarded a $402,115 grant to develop an improved nanoparticle delivery system that enhances [...]